тел. +38 (044) 483-12-82

№4(6) 2023

Укр

DOI 10.37219/2528-8253-2023-4-25

Gogunska IV, Zabolotna DD, Zabrodska LV, Naumova OO, Kalynjuk VM, Smagina TV, Nesterchuk VI

EFFICACY OF MOMETASONE FUROATE IN THE TREATMENT OF PATIENTS WITH INTERMITTENT ALLERGIC RHINITIS WITH SENSITIZATION TO GRASS POLLEN AND CONCOMITANT ALLERGY TO ALTERNARIA ALTERNATA

Gogunska Inna V
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
Center allergic diseases of the upper respiratory tract
Doctor of Medical Sciences, professor
e-mail: innagogunskaya@gmail.com
ORCID ID: https://orcid.org/0000-0001-6952-5057
Scopus ID: 57720990200

Zabolotna Diana D
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine.
Head of Department of Rhinology and Allergology with a group of radiology
Doctor of Medical Sciences, Professor
E-mail: dianazab@ukr.net
ORCID ID: https://orcid.org/0000-0001-7807-8148
Scopus Author ID: 57208163951

Забродська Людмила Валеріївна
Державна установа «Інститут отоларингології ім. проф. О.С. Коломійченка Національної академії медичних наук України»
Керівник Центру алергічних захворювань верхніх дихальних шляхів
Канд. мед. наук
E-mail: zabrodskalv@gmail.com.
ORCID ID: https://orcid.org/0009-0009-0687-0203

Naumova Olga O.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
Center allergic diseases of the upper respiratory tract
Candidate of Medical Sciences
E-mail: dr.onaumova@gmail.com
ORCID ID: https://orcid.org/0000-0002-1318-8319

Kalyniuk Viktoriia M
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine.
Department of Rhinology and Allergology with a group of radiology
Junior researcher
E-mail: artvika3@gmail.com
ORCID ID: https://orcid.org/0009-0002-9792-6100

Smagina Tetyana V.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”
Department of Rhinology and Allergology with radiology group
Candidate of Medical Sciences
Email: smagin1@ukr.net
ORCID ID: https://orcid.org/0000-0002-8349-8275

Nesterchuk Vladislav I.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
Department of Rhinology and Allergology with radiology group
Candidate of Medical Sciences
Email: smagin1@ukr.net
ORCID ID: https://orcid.org/0000-0003-4486-046X

Abstract

Adult patients with intermittent allergic rhinitis with sensitization to grass pollen (first group, 30 subjects) and patients with allergy to grass pollen and concomitant sensitization to Alternaria alternate spores (second group, 30 subjects) were treated with mometasone furoate nasal spray of (Nasonex) 200 mcg per day and levocetirizine 5 mg daily for 30 days. In both groups of the study, there was a pronounced and rapid regression of objective data: swelling of the nasal mucosa, a decrease in the amount of secretions in the nasal cavity, and subjective clinical manifestations: nasal congestion, rhinorrhea, itching in the nose and palate, and sneezing. Patients of both groups reported improvement in quality of life indicators compared to the beginning of the study. The effectiveness of the treatment did not differ in the study groups, although the severity of the allergic process in the second group was significantly higher at the beginning of the treatment. Adverse events in the study were predictable and mild in severity, confirming the favorable safety profile of Nasonex in the treatment of intermittent allergic rhinitis.

Key words: allergic rhinitis, symptoms, pharmacotherapy, mometasone furoate.

Download.PDF

References

  1. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001 Nov;108(5 Suppl): S147-334. doi: 10.1067/mai.2001.118891.
  2. Brożek JL, Bousquet G, Agache I, Agarval A, Bachert K, Bosnic-Antievich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017 Oct;140(4):950-958. doi: 10.1016/j.jaci.2017.03.050.
  3. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008 Aug;122(2 Suppl):S1-84. doi: 10.1016/j.jaci.2008.06.003.
  4. Wise SK, Damask C, Roland LT, Ebert C, Levy JM, et al. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023. Int Forum Allergy Rhinol. 2023 Apr;13(4):293-859. doi: 10.1002/alr.23090.
  5. Yurjev SD, Kurchenko AI, Fedoruk GV. [Algorithm of selecting patients with allergic rhinitis and sensitization to house dust mites to conduct allergen immunotherapy]. Immunology and Allergy: Science and Practice. 2018;(1):46-53. [Article in Ukrainian].
  6. Zubchenko S, Yuriev S. Assessment diagnostic criteria in patients with different clinical and laboratory manifestations of sensitization to house dust mites efficiency and forecasting allergen specific immunotherapy based on allergies component diagnostic. Int. Rev. Allergol. Clin. Immunol. Family Med. 2015;21(4):109-16.
  7. Makarenko OV, Solomko DS. [Pharmacoeconomic evaluation of allergic rhinitis treatment]. Pharmacology and drug toxicology. 2014;39(3):82-7. [Article in Ukrainian].
  8. Szelenyi I. Allergic rhinitis: meaningful and less meaningful combination treatments including reminiscences. Pharmazie. 2014; 69(6): 414-16.
  9. Demoly P, Allaert FA, Lecasble M, Klossek JM. Groupe Pragma. [ERAP, a pharmaco-epidemiologic survey on perennial allergic rhinitis in every day medical practice in France]. Presse Med. 2003 Jun 28;32(23):1066-73. [Article in French].
  10. Demoly P, Allaert FA, Lecasble M. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in everyday general medical practice in France. Allergy. 2002 Jun;57(6):546-54. doi: 10.1034/j.1398-9995.2002.t01-1-13370.x.
  11. Caballer de la Hoz B, Rodríguez M, Fraj J, Cerecedo I, Antolín-Amérigo D, Colás C. Allergic rhinitis and its impact on work productivity in primary care practice and a comparison with other common diseases: The Cross-sectional study to evaluate work Productivity in allergic Rhinitis compared with other common diseases (CAPRI) study. Am J Rhinol Allergy. 2012 Sep-Oct; 26(5):390-4. doi: 10.2500/ajra.2012.26.3799.
  12. Mou YK, Wang HR, Zhang WB, Zhang Y, Ren C, Song XC. Allergic Rhinitis and Depression: Profile and Proposal. Front Psychiatry. 2022 Jan 4:12:820497. doi: 10.3389/fpsyt.2021.820497.
  13. HsiehM-T, LiangSH-Y, Yang Y-H, Kuo T-Y, Lin T-Y,  et al. Allergic rhinitis increases the risk of incident panic disorder among young individuals: A nationwide population-based cohort study in Taiwan. J Affect Disord. 2019 Jun 1:252:60-67. doi: 10.1016/j.jad.2019.04.037.
  14. Fang BJ, Tonelli LH, Soriano JJ, Postolache TT. Disturbed sleep: linking allergic rhinitis, mood and suicidal behavior. Front Biosci (Schol Ed). 2010 Jan 1;2(1):30-46. doi: 10.2741/s44.
  15. Rodinkova VV, Yuriev SD. [Sensitivity of the population in Ukraine to pollenosis factors according to the ALEX molecular allergy diagnostics]. Klinichna immunolohiia. Alerholohiia. Infektolohiia. 2019;115(2):22-26. [Article in Ukrainian].
  16. Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3. doi: 10.1016/j.jaci.2019.06.049.
  17. [Unified clinical protocol of primary, secondary (specialised) and tertiary (highly specialised) medical care “Allergic rhinitis”]. Klinichna immunolohiia. Alerholohiia. Infektolohiia. 2019;115(2):28-39. [In Ukrainian].
  18. Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016 Aug;138(2):367-374.e2. doi: 10.1016/j.jaci.2016.03.025.
  19. Shah S A,Berger R L,McDermott J, Gupta P, Monteith D, Connor A, Lin Regional deposition of mometasone furoate nasal spray suspension in humans. Allergy Asthma Proc. 2014 Nov 21. doi: 10.2500/aap.2015.35.3817.
  20. Sharpe SA, Sandweiss V, Tuazon J, Giordano M, Witchey-Lakshmanan L, Hart J, Sequeira Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev Ind Pharm. 2003 Oct;29(9):1005-12. doi: 10.1081/ddc-120025457.
  21. Minshall E, Ghaffar O, Cameron L, O’Brien F, Quinn H, Rowe-Jones J, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg. 1998 May;118(5):648-54. doi: 10.1177/019459989811800514.
  22. Juniper EF, Stahl E, Doty RL, Simons FER, Allen DB, Howarth PH. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol. 2005 Mar;115(3 Suppl 1):S390-413. doi: 10.1016/j.jaci.2004.12.014.